DC+CIK联合常规化疗对延长晚期NSCLC患者生存期、提高生活质量的作用

• 投稿 • 上一篇

DC+CIK联合常规化疗对延长晚期NSCLC患者生存期、提高生活质量的作用

张志强,王梓瑛,张宇,王晓舟,郑爽,赫丽杰

辽宁省人民医院肿瘤内科,辽宁省人民医院肿瘤内科,辽宁省人民医院肿瘤内科,辽宁省人民医院肿瘤内科,辽宁省人民医院肿瘤内科,辽宁省人民医院肿瘤内科

收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2016-02-25

Effects of DC,CIK Combined with Conventional Chemotherapy on Prolonging Survival,Improving Quality of Life of Patients with Advanced NSCLC

Zhang Zhi-qiang, Wang Zi-ying, Zhang Yu

Department of Medical Oncology,Liaoning Provincial People′s Hospital,Department of Medical Oncology,Liaoning Provincial People′s Hospital,Department of Medical Oncology,Liaoning Provincial People′s Hospital,Department of Medical Oncology,Liaoning Provincial People′s Hospital,Department of Medical Oncology,Liaoning Provincial People′s Hospital and Department of Medical Oncology,Liaoning Provincial People′s Hospital

Received:1900-01-01 Revised:1900-01-01 Online:2016-02-25

摘要/Abstract

摘要： 目的：探讨晚期NSCLC患者生存期、生活质量受DC+CIK联合常规化学治疗（化疗）的影响。方法：随机选取2012年5月～2015年5月我院收治的120例晚期非小细胞肺癌（NSCLC）患者，依据随机数字表法分这些患者为两组，即研究组（n=60）和对照组（n=60）。给予对照组患者单纯常规化疗治疗，给予研究组患者DC+CIK联合常规化疗治疗，然后对两组患者的临床疗效、免疫功能、PFS、OS及1年、2年生存率、生活质量进行统计分析。结果：研究组患者的DCR90.0%（54/60）显著高于对照组73.3%（44/60）（P＜0.05），PFS显著长于对照组（P＜0.05），1年、2年生存率均显著高于对照组（P＜0.05），KPS评分显著高于对照组（P＜0.05），但两组患者的ORR11.7%（7/60）、5.0%（3/60），CD3+、CD3+CD4+、CD3+CD8+T细胞、CD4+/CD8+T细胞比值、CD3-CD56+NK细胞，OS之间的差异均不显著（P＞0.05）。结论：DC+CIK联合常规化疗能够有效延长晚期NSCLC患者生存期、提高生活质量。

Abstract: Objective: To investigate the effects of DC+CIK combined with conventional chemotherapy on survival,quality of life of patients with advanced NSCLC.Methods:120 cases of patients with advanced NSCLC in our hospital from May 2012 to May 2015 were randomly selected,these patients were randomly divided into two groups according to a random table, the study group(n=60) and control group(n=60).The control group were given conventional chemotherapy treatment alone,while the study group were given DC+CIK therapy combined with conventional chemotherapy,and then the clinical efficacy,immune function,PFS,OS,and 1 year,2-year survival,quality of life of the two groups were statistically analyzed.Results:The DCR90.0%(54/60) of the study group was significantly higher than the control group 73.3%(44/60)(P＜0.05),the PFS was significantly longer(P＜0.05),the 1-year, 2-year survival were significantly higher(P＜0.05),the KPS score was significantly higher than the control group(P＜0.05),but the differences of ORR11.7%(7/60),5.0%(3/60),CD3+, CD3 + CD4 +, CD3 + CD8 + T cells, CD4 + / CD8 + T cell ratio,CD3-CD56 + NK cells,OS between the two groups were not significant(P＞0.05).Conclusion:DC+CIK combined with conventional chemotherapy can prolong survival,improve quality of life of patients with advanced NSCLC,so is worthy of promotion in the clinical.

张志强,王梓瑛,张宇,王晓舟,郑爽,赫丽杰. DC+CIK联合常规化疗对延长晚期NSCLC患者生存期、提高生活质量的作用[J]. .

Zhang Zhi-qiang, Wang Zi-ying, Zhang Yu. Effects of DC,CIK Combined with Conventional Chemotherapy on Prolonging Survival,Improving Quality of Life of Patients with Advanced NSCLC[J]. .

快速检索引用检索图表检索高级检索